As filed with the Securities and Exchange Commission on February 25, 2022
Registration No. 333-
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-8
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
SHOCKWAVE MEDICAL, INC.
(Exact Name of Registrant as Specified in its Charter)
Delaware |
3841 |
27-0494101 |
(State or Other Jurisdiction of |
(Primary Standard Industrial Classification Code Number) |
(I.R.S. Employer |
|
5403 Betsy Ross Drive Santa Clara, California 95054 |
|
(Address of Principal Executive Offices) |
Shockwave Medical, Inc. 2019 Equity Incentive Plan (Full Titles of the Plans) |
|
Douglas Godshall Shockwave Medical, Inc. |
|
|
(Name and address of agent for service)
|
|||
|
(510) 279-4262 |
|
|
(Telephone Number, Including Area Code, of Agents for Service) |
|||
|
With copies to: |
||
Alan F. Denenberg Jason Bassetti Davis Polk & Wardwell LLP 1600 El Camino Real Menlo Park, CA 94025 (650) 752-2000
|
|
Hajime Tada General Counsel and Corporate Secretary Shockwave Medical, Inc. 5403 Betsy Ross Drive Santa Clara, California 95054 (510) 279-4262 |
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer☒ |
Accelerated filer ☐ |
Non-accelerated filer ☐ (Do not check if a smaller reporting company) |
Smaller reporting company ☐ |
|
Emerging Growth Company ☐ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐
REGISTRATION OF ADDITIONAL SHARES PURSUANT TO GENERAL INSTRUCTION E
This Registration Statement on Form S-8 is being filed for the purpose of increasing the number of securities of the same class as other securities for which Registration Statements of the Registrant on Form S-8 relating to the same employee benefit plans are effective. The Registrant previously registered shares of its common stock for issuance under the Registrant’s 2019 Equity Incentive Plan and the Registrant’s Employee Stock Purchase Plan under Registration Statements on Form S-8 filed with the Securities and Exchange Commission on March 7, 2019 (File No. 333-230113), March 27, 2020 (File No. 333-237448) and February 26, 2021 (File No. 333-253623). Pursuant to General Instruction E to Form S-8, this Registration Statement hereby incorporates by reference the contents of the Registration Statements referenced above.
INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
Item 8. Exhibits
The following exhibits are filed as part of this Registration Statement:
Exhibit |
Description |
|
|
5.1* |
|
23.1* |
|
23.2* |
Consent of Davis Polk & Wardell LLP (included in Exhibit 5.1) |
24.1* |
|
99.1(1) |
2019 Equity Incentive Plan and Form of Stock Option Agreement thereunder |
99.2(2) |
Form of Global Restricted Stock Unit Agreement under the 2019 Equity Incentive Plan |
99.3(3) |
|
107* |
* |
Filed herewith. |
(1) |
Filed as Exhibit 10.4 to the Registrant’s Amendment No. 1 to Registration Statement on Form S-1 (No. 333-229590), filed on February 25, 2019 and incorporated herein by reference. |
(2) |
Filed as Exhibit 10.5 to the Registrant’s Annual Report on Form 10-K (No. 001-38829), filed on February 25, 2022 and incorporated herein by reference. |
(3) |
Filed as Exhibit 10.5 to the Registrant’s Amendment No. 1 to Registration Statement on Form S-1 (No. 333-229590), filed on February 25, 2019 and incorporated herein by reference. |
Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Santa Clara, State of California, on the 25th day of February 2022.
Shockwave Medical, Inc. |
|
By: |
/s/ Douglas Godshall |
Name: Title: |
Douglas Godshall President and Chief Executive Officer |
POWER OF ATTORNEY AND SIGNATURES
Know all persons by these presents, that each person whose signature appears below, constitutes and appoints each of Douglas Godshall, Dan Puckett, and Trinh Phung as his or her true and lawful attorney-in-fact, proxy and agent, upon the action of such appointee, with full power of substitution and resubstitution, to do any and all acts and things and execute, in the name of the undersigned, any and all instruments which each of said attorneys-in-fact, proxies and agents may deem necessary or advisable in order to enable Shockwave Medical, Inc. to comply with the Securities Act, and any requirements of the Commission in respect thereof, in connection with the filing with the Commission of this Registration Statement under the Securities Act, including specifically but without limitation, power and authority to sign the name of the undersigned to such Registration Statement, and any amendments to such Registration Statement (including post-effective amendments), and to file the same with all exhibits thereto and other documents in connection therewith, with the Commission, to sign any and all applications, registration statements, notices or other documents necessary or advisable to comply with applicable state securities laws, and to file the same, together with other documents in connection therewith with the appropriate state securities authorities, granting unto each of said attorneys-in-fact, proxies and agents full power and authority to do and to perform each and every act and thing requisite or necessary to be done in and about the premises, as fully and to all intents and purposes as the undersigned might or could do in person, hereby ratifying and confirming all that each of said attorneys-in-fact, proxies and agents, or their or his or her substitutes, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated:
Signature |
Title |
Date |
|
|
|
/s/ Douglas Godshall |
President, Chief Executive Officer & Director (principal executive officer) |
February 25, 2022 |
Douglas Godshall |
|
|
/s/ Dan Puckett |
Chief Financial Officer (principal financial officer) |
February 25, 2022 |
Dan Puckett |
|
|
/s/ Trinh Phung |
Vice President of Finance (principal accounting officer) |
February 25, 2022 |
Trinh Phung |
|
|
/s/ C. Raymond Larkin |
Chairman & Director |
February 25, 2022 |
C. Raymond Larkin, Jr. |
|
|
/s/ Laura Francis |
Director |
February 25, 2022 |
Laura Francis |
|
|
/s/ Frederic Moll |
Director |
February 25, 2022 |
Frederic Moll, M.D. |
|
|
/s/ Antoine Papiernik |
Director |
February 25, 2022 |
Antoine Papiernik |
|
|
/s/ Maria Sainz |
Director |
February 25, 2022 |
Maria Sainz |
|
|
/s/ Sara Toyloy |
Director |
February 25, 2022 |
Sara Toyloy |
|
|
/s/ F.T Jay Watkins |
Director |
February 25, 2022 |
F.T. “Jay” Watkins |
|
|
February 25, 2022 |
Exhibit 5.1
Shockwave Medical, Inc.
5403 Betsy Ross Drive
Santa Clara, California 95054
Ladies and Gentlemen:
We have acted as special counsel to Shockwave Medical, Inc., a Delaware corporation (the “Company”), and are delivering this opinion in connection with the Company’s Registration Statement on Form S-8 (the “Registration Statement”) filed with the Securities and Exchange Commission pursuant to the Securities Act of 1933, as amended, for the registration of 1,417,778 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share, issuable pursuant to the Company’s 2019 Equity Incentive Plan and Employee Stock Purchase Plan (together, the “Plans”).
We, as your counsel, have examined originals or copies of such documents, corporate records, certificates of public officials and other instruments as we have deemed necessary or advisable for the purpose of rendering this opinion.
In rendering the opinion expressed herein, we have, without independent inquiry or investigation, assumed that (i) all documents submitted to us as originals are authentic and complete, (ii) all documents submitted to us as copies conform to authentic, complete originals, (iii) all signatures on all documents that we reviewed are genuine, (iv) all natural persons executing documents had and have the legal capacity to do so, (v) all statements in certificates of public officials and officers of the Company that we reviewed were and are accurate and (vi) all representations made by the Company as to matters of fact in the documents that we reviewed were and are accurate.
On the basis of the foregoing, we are of the opinion that the Shares have been duly authorized and, when and to the extent issued pursuant to the Plans upon receipt by the Company of the consideration for the Shares specified therein, will be validly issued, fully paid and non-assessable.
We are members of the Bars of the States of New York and California and the foregoing opinion is limited to the laws of the State of New York and the General Corporation Law of the State of Delaware.
We hereby consent to the filing of this opinion as Exhibit 5.1 to the Registration Statement. In giving this consent, we do not admit that we are in the category of persons whose consent is required under Section 7 of the Securities Act.
Very truly yours,
/s/ Davis Polk & Wardwell LLP
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the Registration Statement on Form S-8 pertaining to the ShockWave Medical, Inc. 2019 Equity Incentive Plan and the ShockWave Medical, Inc. Employee Stock Purchase Plan, of our reports dated February 25, 2022, with respect to the consolidated financial statements of Shockwave Medical, Inc. and the effectiveness of internal control over financial reporting of Shockwave Medical, Inc. included in its Annual Report (Form 10-K) for the year ended December 31, 2021, filed with the Securities and Exchange Commission.
/s/ Ernst & Young LLP |
San Jose, California |
February 25, 2022 |
1
Exhibit 107
Calculation of Filing Fee Tables
Form S-8
(Form Type)
Shockwave Medical, Inc.
(Exact Name of Registrant as Specified in its Charter)
Newly Registered Securities
Security Type |
Security Class Title |
Fee Calculation Rule |
Amount Registered(1) |
Proposed Maximum Offering Price Per Unit(3) |
Maximum Aggregate Offering Price(3) |
Fee Rate |
Amount of Registration Fee(4) |
Equity |
Common stock, par value $0.001 per share |
Rule 457(c) and Rule 457(h) |
1,417,778(2) |
$145.67 |
$198,779,576 |
0.0000927 |
$18,428 |
Total Offering Amounts |
|
$198,779,576 |
|
$18,428 |
|||
Total Fee Offsets(5) |
|
|
|
— |
|||
Net Fee Due |
|
|
|
$18,428 |
(1) |
Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the “Securities Act”), this Registration Statement on Form S-8 shall cover any additional shares of common stock, $0.001 par value per share (“Common Stock”) of the Registrant that become issuable under the Employee Stock Purchase Plan (the “ESPP”) and the 2019 Equity Incentive Plan (the “2019 Plan”) by reason of any stock dividend, stock split, recapitalization, or other similar transaction effected without the Registrant’s receipt of consideration which results in an increase in the number of the outstanding shares of Common Stock. |
(2) |
Represents: (i) 1,063,334 shares of Common Stock that were automatically added to the shares reserved for issuance under the 2019 Plan on January 1, 2022 pursuant to the provision of the 2019 Plan providing for an annual automatic increase in the number of authorized shares reserved and available for issuance under the 2019 Plan and (ii) 354,444 shares of Common Stock that were automatically added to the shares reserved for issuance under the ESPP on January 1, 2022 pursuant to the provision of the ESPP providing for an annual automatic increase in the number of authorized shares reserved and available for issuance under the ESPP. |
(3) |
Estimated under Rules 457(c) and (h) of the Securities Act solely for the purpose of calculating the registration fee on the basis of the average of the high and low prices of the Common Stock on February 17, 2022, as reported by the Nasdaq Global Select Market. Under the ESPP, the purchase price of a share of Common Stock is equal to 85% of the fair market value of the Common Stock on the offering date or the purchase date, whichever is less. |
(4) |
Rounded up to the nearest cent. |
(5) |
The Registrant does not have any fee offsets. |